Grants Awarded

The METAvivor Research Program was established in 2009 with the specific goal of funding stage IV metastatic breast cancer research to one day, end death from metastatic breast cancer (MBC). The following list includes current and past grant recipients along with their progress reports.

If you would like to go back to the main research page, click here

ACTIVE GRANT RECIPIENTS



2020

Adrian Lee, PhD

University of Pittsburgh, UPMC Hillman Cancer Center

Targeting RET for the treatment of breast cancer brain metastasis

Abstract Report

Blake “Eason” Hildreth, DVM, MS, PhD

University of Alabama, Birmingham

Targeting the CSF1R/PU.1 axis and PU.1/BET super-enhancer regulome in breast cancer bone metastasis

Abstract Report

Julie Di Martino, PhD

Icahn School of Medicine at Mount Sinai

Targeting dormant breast cancer cells with ACE inhibitors

Abstract Report

Nathan Reticker-Flynn, PhD

Stanford University

Targeting lymph node-induced immune tolerance to treat metastatic breast cancer

Abstract Report

Lou Song, PhD

University of Virginia

Oncogenic TRIM37 is a new driver of metastasis in triple negative breast cancer patients

Abstract Report

Tae-Hyung Kim, PhD

University of New Mexico

Harnessing cell mechanotype to regulate the immune evasion of highly metastatic breast cancer cells

Abstract Report

Reva Basho, MD

Cedars-Sinai Medical Center Samuel Oschin Comprehensive Cancer Institute

Presented by Metavivor Facebook Fundraisers

Tucatinib in Combination with Pembrolizumab and Trastuzumab for Patients with HER2+ Breast Cancer Brain Metastases

Abstract Report

Isaac Chan, MD, PhD

UT Southwestern Medical Center

Presented by #Lindasbug: A VW Beetle Fundraiser in Memory of Linda Kreizenbeck

Using natural killer cells to eliminate breast cancer metastases

Abstract Report

Jessica Christenson, PhD

University of Colorado Anschutz Medical Campus

Presented by Metavivor Facebook Fundraisers

Repurposing Lung Microenvironment Targeted Therapies for the Treatment of Established Breast Cancer Lung Metastases

Abstract Report

Erin Howe, PhD

University of Notre Dame-Harper Cancer Research Institute

Presented in memory of Erin Remme by Minneapolis Metsquerade

Targeting endosomal trafficking to enhance immune recognition of breast cancer brain metastases

Abstract Report

Natasha Hunter, MD

University of Washington

Presented by Metavivor Facebook Fundraisers

Tissue and liquid biopsy for breast cancer patients with bone-only metastases

Abstract Report

Dennis Jones, PhD

Boston University

Presented by Metavivor Facebook Fundraisers

Targeting breast cancer plasticity and immunosuppression in metastatic lymph nodes

Abstract Report

2019

Nancy Lin, MD

Dana-Farber Cancer Institute

Overcoming Treatment Resistance in Breast Cancer Brain Metastases

Abstract Report

Bolin Liu, PhD

Department of Genetics Stanley S. Scott Cancer Center School of Medicine Louisiana State University Health Sciences Center

Presented in Memory of Cecilia “CeCe” Curry, METAvivor Board Member

IGF-2 in Herceptin refractory HER2-positive breast cancer

Abstract Report

Paul Lockman, PhD

West Virginia University

Timing of radiotherapy and chemotherapy to improve drug effect in brain metastases of breast cancer

Abstract Report

Deepali Sachdev, BSc, MSc, PhD

Regents University

Presented by 2019 NYFW + #Cancerland in memory of Champagne Joy

Development of natural killer cell based tri-specific killer engagers (TriKEs) as novel immunotherapy for metastatic breast canc

Abstract Report

Robert Weinberg, PhD

Whitehead Institute for Biomedical Research

Mechanisms of Acquired Adaptation of Disseminated Breast Cancer Cells

Abstract Report

Fei Xing, PhD

Wake Forest University

Treating breast cancer brain metastasis with immune checkpoint inhibitor and c-Met targeting agent

Abstract Report

Massimo Cristofanilli, MD

Northwestern University

Presented In Memory of Karen Presswood, Co-Founder of METAvivor

Unravelling New Cytokine-Mediated Mechanisms to Enhance Response to CDK4/6 inhibition in ER+/HER2-Metastatic Breast Cancer

Abstract Report

Andrew Ewald, PhD

Johns Hopkins University, School of Medicine

Presented In Memory of Avis Halberstadt, Co-Founder of Metavivor

Targeting the survival pathways required by established breast cancer metastases

Abstract Report

Carol Lange, PhD

University of Minnesota

Presented In Memory of Rhonda Rhodes, Co-Founder of Metavivor

Targeting Activated Progesterone Receptors in Metastatic Breast Cancer

Abstract Report

Prasanna Alluri, MD, PhD

UT Southwestern Medical Center at Dallas

Presented in honor of Erin Remme by Minneapolis Metsquerade

Identifying Therapeutic Vulnerabilities in RB1-negative, ER-positive Breast Cancers

Abstract Report

Lucia Borriello, PhD

Albert Einstein College of Medicine

Presented by 2019 New York Fashion Week

Targeting the Mechanism of Re-Dissemination and Metastasis in Stage IV Breast Cancer

Abstract Report

Joshua Drago, MD

Memorial Sloan Kettering Cancer

Presented by METAvivors of New Jersey

The intestinal microbiome and response to chemoimmunotherapy in patients with metastatic triple negative breast cancer (MTNBC)

Abstract Report

Mick Edmonds, PhD, MS

UAB School of Medicine

Presented In Memory of Kristin Todd

A novel strategy targeting SRC tyrosine kinase for breast cancer metastasis

Abstract Report

Colt Egelston, PhD

City of Hope

Presented In Memory of Angie Powell by Northwest Arkansas Metsquerade

Bispecific monoclonal antibodies for treatment of advanced breast cancer

Abstract Report

Jeremy Force, DO, MA

Duke University

Presented In Memory of Kristie Godwin Rolan by Triangle Metsquerade

Discovery and validation of putative oncogenic ROS1 alterations in breast cancer

Abstract Report

Jamie Fornetti, BA, PhD

Huntsman Cancer Institute, University of Utah

Presented by Abbey Rapoport

Novel RON Inhibitors for the Treatment of Metastatic Breast Cancer

Abstract Report

Antonio Giordano, MD, PhD

Medical University of South Carolina

Presented In Honor of Michael Kovarik by 2019 New York Fashion Week

Phase 1 clinical trial of Polo-like kinase 1 inhibition with nab-paclitaxel in TP53 mutated metastatic triple negative breast ca

Abstract Report

Sheheryar Kabraji, BMBCh

Dana-Farber Cancer Institute

Presented by 2019 METAbash

Targeting drug-resistant quiescent cancer cells in breast cancer brain metastases

Abstract Report

Jungwoo Lee, PhD

University of Massachusetts Amherst

Tissue-engineered bone to determine the impact of chemotherapy-induced premature aging in breast tumor metastasis

Abstract Report

Michael Lukey, PhD

Cornell University

Presented by Minneapolis Metsquerade in honor of Erin Remme

Targeting the unique metabolic profile of brain metastases in breast cancer

Abstract Report

Madeline Oudin, BSc, MSc, PhD

Tufts University

Presented by METAribbon Challengers

Investigating how obesity-driven changes in the tumor microenvironment promote metastatic outgrowth and chemoresistance in metas

Abstract Report

Lijuan Sun, PhD

Cold Spring Harbor Laboratory

Presented In Memory of Rebecca McNally Gilden - Blessed mother, wife, daughter, engineer, friend and breast cancer advocate

Reprogramming innate-adaptive immune interactions to eliminate metastatic breast cancer

Abstract Report

Stuart Martin, PhD

University of Maryland School of Medicine

Presented In Memory of Wendy Taylor by Northwest Arkansas Metsquerade

Reducing the risk of chemotherapy-induced scattering of metastatic triple-negative breast tumors

Abstract Report

Danny Welch, PhD

University of Kansas Cancer Center

Presented In Memory of Valerie Wright by Northwest Arkansas Metsquerade

New inhibitors of breast cancer metastasis

Abstract Report

Andrei Bakin, PhD

Roswell Park Cancer Center

A Novel Combination Therapy to Improve Treatment of Metastatic Breast Cancer

Abstract Report

Sanchita Bhatnagar, PhD

University of Virginia School of Medicine

Targeting the mechanisms of oncogenic TRIM37 in metastatic triple negative breast cancer

Abstract Report

Rolf Brekken, PhD

UT Southwestern

Pleiotrophin as a driver of the immune metastatic niche

Abstract Report

Andrew Brenner, MD, PhD

Mays Cancer Center

Presented In Memory of Tarah Harvey by Minneapolis Metsquerade

Permeability of Sacituzumab Govitecan in Breast Cancer Brain Metastases

Abstract Report

Barbara Fingleton, PhD

Vanderbilt University

Presented In Memory of Destiny Rivera and Stephanie Sunday by Orlando Metsquerade

Tumor targeting of an immune super-activator in male and female metastatic breast cancer

Abstract Report

Barry Hudson, PhD

University of Miami

Presented in memory of Amanda De Fiebre by Southwest Florida Metsquerade

Therapeutic targeting of RAGE in metastatic breast cancer

Abstract Report

Yibin Kang, PhD

Princeton University

Presented by The Fraternal Order of Eagles

Preventing Regulatory T cell Induction to Enhance Immunity Against Breast Cancer Metastases

Abstract Report

Stephen Kron, MD, PhD

The University of Chicago

Mechanisms determining local and systemic anti-tumor immune response after metastasis-directed image-guided radiation combined w

Abstract Report

Sandra McAllister, PhD

Brigham and Women's Hospital; Harvard Medical School

Presented In Memory of Lauren Smoke by Chicago Metsquerade

A new approach to identifying effective therapeutic strategies that eliminate de novo and recurrent stage IV triple-negative bre

Abstract Report

Yusuke Shiozawa, MD, PhD

Wake Forest University

An osteolytic bone lesion-targeted radiopharmaceutical for bone metastatic breast cancer

Abstract Report

Zena Werb, PhD

University of California, San Francisco

Presented by METAvivor Facebook Fundraisers

Identification of Novel Cell Targets for Metastatic Breast Cancer Therapy

Abstract Report

Jing Yang, PhD

University of California, San Diego

Overcoming therapy resistance in TNBC metastases through targeted inhibition of Periostin

Abstract Report

Dihua Yu, PhD

The University of Texas

Presented In loving memory of Tiffany Foust and Kriss Fierro by Monica Hill's Be Bold and Behold

Impeding Breast Cancer Brain Metastasis by Blocking CCR2+ Myeloid Cell Infiltration

Abstract Report

2018

JULIO AGUIRRE-GHISO, PhD

Icahn School of Medicine

Targeting Intrinsic And Immune Mechanisms In Persistent Dormant Cancer Cells In Stage IV Breast Cancer

Abstract Report

CHARLES CLEVENGER, MD, PhD

Virginia Commonwealth University

Inhibition of breast cancer metastatic outgrowth with non-immunosuppressive cyclosporine

Abstract Report

VERA DONNENBERG, PhD

University of Pittsburgh School of Medicine UPMC Hillman Cancer Center

Assays to determine optimal dosing and therapeutic effects of localized immunotherapy for established metastatic breast cancer t

Abstract Report

GLORIA ECHEVERRIA, PhD

MD Anderson Cancer Center

Elucidation and functionalization of transcriptomic heterogeneity of established multi-organ metastases in patient-derived xenog

Abstract Report

DORRAYA EL-ASHRY, PhD

University of Minnesota School of Medicine

Eliminate breast cancer metastasis by targeting the tumor microenvironment

Abstract Report

XU FENG, PhD

University of Alabama at Birmingham

Development of Targeted Drugs for Treating Breast Cancer Bone Metastasis

Abstract Report

JANET FUNK, MD

University of Arizona Cancer Center

Improving Survival in Stage IV Breast Cancer by Targeting Dormant Breast Cancer Cells in Bone

Abstract Report

ANA GARRIDO-CASTRO, MD

Dana-Farber Cancer Institute

Identifying predictive biomarkers of response to PD-1 inhibition in metastatic triple-negative breast cancer

Abstract Report

MARK HEADLEY, PhD

Fred Hutchinson Cancer Research Center

Monocyte Contribution To Lung Metastasis Of Breast Cancer

Abstract Report

FRANSISCA LEONARD, PhD

Houston Methodist Hospital Research Institute

CRISPR-nanoparticle for macrophage reprogramming: New therapeutic strategy for breast cancer liver metastasis

Abstract Report

SOPHIA LUNT, PhD

Michigan State University

Targeting Sialic Acid Metabolism to Stop Metastatic Breast Cancer

Abstract Report

ELIZABETH MCDONALD, MD, PhD

University of Pennsylvania

In vivo visualization and quantification of pharmacodynamics response to PARPi therapy

Abstract Report

ERIK NELSON, PhD

University of Illinois

Targeting an immune-suppressive cholesterol metabolite in the treatment metastatic breast cancer

Abstract Report

JOSH NEMAN, PhD

University of Southern California

Chemotherapy and tau interplay permeabilize BBB and facilitate brain metastasis

Abstract Report

AXEL SCHÖNTHAL, PhD

University of Southern California

Controlled Opening of the Blood-Brain Barrier to Achieve Therapeutic Access of Trastuzumab in HER2-Positive Brain Metastases

Abstract Report

BRAD ST CROIX, PhD

National Cancer Institute

Improving Immunotherapies for Advanced Metastatic Breast Cancer

Abstract Report

RACHEL STEWART, PhD

University of Kentucky

Characterizing Metastatic Breast Cancer Heterogeneity through Post-Mortem Tissue Collection

Abstract Report

WEI TAO, PhD

Harvard Medical School/Brigham and Women’s Hospital

Multi-staged delivery system overcoming the physiological barriers for metastatic breast cancer (MBC) therapy

Abstract Report

MICHAEL WENDT, PhD

Purdue University

Enhancing anti-metastatic immunity through targeted inhibition of SHP2 phosphatase

Abstract Report

THOMAS WESTBROOK, PhD

Baylor College of Medicine

Microenvironment response disparities of metastatic TNBC to multi-tyrosine kinase inhibition

Abstract Report

DIHUA YU, MD, PhD

MD Anderson Cancer Center

Combating Breast Cancer Brain Metastasis by Blocking CDK5 Driver Kinase Function

Abstract Report

FIONA YULL, PhD

Vanderbilt School of Medicine

Macrophage-based immunotherapy for eradication of pre-existing breast cancer metastases

Abstract Report

ANDREI GOGA, MD, PhD

University of California, San Francisco

Targeting the MYC Pathway in Metastatic Breast Cancer

Abstract Report

View Past Grant Recipients